Clinical Takeaway
In this pilot RCT of 20 adults with clinically diagnosed insomnia, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time compared to placebo, suggesting that at least one common cannabinoid dosing regimen may not improve and could modestly worsen objective sleep duration. High-density EEG allowed detailed examination of sleep architecture changes, providing more rigorous measurement than self-report alone. These findings underscore that popularity of cannabis as a sleep aid does not guarantee effectiveness, and patients should discuss evidence-based expectations with their clinician before use.
#9 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This pilot study provides the first high-density EEG characterization of how a standardized THC/CBD combination affects sleep architecture in patients with diagnosed insomnia disorder, addressing a critical gap between widespread clinical use and objective neurophysiological evidence. The rigorous methodology examining both acute sleep effects and next-day cognitive function offers clinicians evidence-based data necessary to counsel patients on cannabinoid efficacy and safety as a sleep intervention.
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
Abstract: Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
😴 This pilot study provides encouraging objective evidence that a 10:20 THC-to-CBD ratio may improve sleep architecture in insomnia disorder, yet several limitations warrant cautious interpretation before clinical implementation. The small sample size of 20 patients, predominance of female participants (80%), and single-dose design limit generalizability and our ability to assess safety with repeated dosing or in diverse populations. Critical unknowns remain regarding optimal dosing, patient selection criteria, potential next-day cognitive or motor impairment, and how these cannabinoids interact with concurrent medications commonly used by insomnia patients. Additionally, the study does not address tolerance development, rebound insomnia upon discontinuation, or longer-term efficacy beyond acute administration. For practitioners considering cannabinoids as a sleep intervention, this work suggests potential benefit warrants further investigation, but current evidence is insufficient to recommend it as a first-line agent; it may be most appropriate as an adjunctive option in carefully selected patients who have failed conventional therapies and who can
| |